Gossamer Bio Inc (GOSS)

$0.45 +0.01 (1.97%)
Market Cap 102.66M
Revenue (ttm) 48.47M
Net Income (ttm) -170.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -351.50%
Debt to Equity Ratio 0.00
Volume 4,082,700
Avg Vol 18,810,051
Day's Range N/A - N/A
Shares Out 234.70M
Stochastic %K 85%
Beta 2.16
Analysts Sell
Price Target $3.68

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to devel...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 684 1300
Address:
3115 Merryfield Row, Suite 120, San Diego, United States
OnlyFibs
OnlyFibs Apr. 18 at 4:31 AM
$GOSS Phase 3 technically failed but the drug worked — 28m improvement vs 14m placebo. FDA meeting pending. $180M cash. $1.00 analyst PT. Biggest buy volume week since before the crash. 🐂 FDA signals path → $0.54 → $0.66 → $1.00 🐻 No path forward → Nasdaq compliance fails → sub-$0.30 ⚠️ Investor lawsuit filed, bid price deficiency notice received — lots of risk but someone is buying this dip hard#GOSS #Biotech #hovdid
0 · Reply
CS_Charts
CS_Charts Apr. 16 at 6:38 PM
$GOSS High risk / high reward biotech setup. Seralutinib in PAH is the whole story here. If Phase 3 delivers, this could re-rate hard given the unmet need and inhaled delivery advantage. Market is clearly pricing in significant execution risk. Key watch: upcoming clinical data + cash runway (possible dilution risk). Not for the faint of heart, but risk/reward starts to look asymmetric at these levels.
0 · Reply
EldarGman
EldarGman Apr. 16 at 5:54 PM
$BTM Nice stock🚀🚀🚀 $SIDU $GOSS $ROLR
0 · Reply
redbeamgold
redbeamgold Apr. 16 at 1:09 PM
$GOSS are we expecting a pr on the scans this month?
1 · Reply
Waagie
Waagie Apr. 16 at 11:07 AM
$GOSS 💪
0 · Reply
Hahaha111
Hahaha111 Apr. 15 at 2:45 PM
$GOSS is 0.50 likely the top - short term? or will this continue to a dollar
1 · Reply
Cheaslea76
Cheaslea76 Apr. 15 at 2:43 PM
$GOSS 😁💪🏽🫶🏽😎
0 · Reply
Sinimini
Sinimini Apr. 15 at 1:40 PM
$GOSS
0 · Reply
Waagie
Waagie Apr. 15 at 1:39 PM
$GOSS
0 · Reply
Fettenajs2026
Fettenajs2026 Apr. 15 at 1:35 PM
$GOSS 0.50 here we come
0 · Reply
Latest News on GOSS
Shareholders who lost money in Gossamer Bio, Inc (NASDAQ: GOSS) Should Contact Wolf Haldenstein Immediately

Apr 13, 2026, 8:32 AM EDT - 5 days ago

Shareholders who lost money in Gossamer Bio, Inc (NASDAQ: GOSS) Should Contact Wolf Haldenstein Immediately

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 4:01 PM EDT - 4 weeks ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1

Mar 5, 2026, 6:16 AM EST - 6 weeks ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1

BWAY DH

GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm

Mar 1, 2026, 4:07 PM EST - 6 weeks ago

GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Feb 23, 2026, 12:40 PM EST - 7 weeks ago

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 23, 2026, 11:26 AM EST - 7 weeks ago

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks

Feb 23, 2026, 9:57 AM EST - 7 weeks ago

Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Feb 23, 2026, 8:11 AM EST - 7 weeks ago

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Feb 23, 2026, 8:00 AM EST - 7 weeks ago

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 5:30 PM EST - 3 months ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 24, 2025, 4:01 PM EST - 5 months ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:01 PM EST - 5 months ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:41 AM EDT - 7 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 25, 2025, 7:31 AM EDT - 7 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 22, 2025, 7:31 AM EDT - 7 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 29, 2025, 7:31 AM EDT - 8 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 9 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Jun 16, 2025, 7:31 AM EDT - 10 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Feb 3, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:46 AM EDT - 2 years ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 6, 2024, 7:30 AM EDT - 2 years ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

May 3, 2024, 8:02 AM EDT - 2 years ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 12, 2024, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 13, 2023, 4:01 PM EST - 2 years ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

OnlyFibs
OnlyFibs Apr. 18 at 4:31 AM
$GOSS Phase 3 technically failed but the drug worked — 28m improvement vs 14m placebo. FDA meeting pending. $180M cash. $1.00 analyst PT. Biggest buy volume week since before the crash. 🐂 FDA signals path → $0.54 → $0.66 → $1.00 🐻 No path forward → Nasdaq compliance fails → sub-$0.30 ⚠️ Investor lawsuit filed, bid price deficiency notice received — lots of risk but someone is buying this dip hard#GOSS #Biotech #hovdid
0 · Reply
CS_Charts
CS_Charts Apr. 16 at 6:38 PM
$GOSS High risk / high reward biotech setup. Seralutinib in PAH is the whole story here. If Phase 3 delivers, this could re-rate hard given the unmet need and inhaled delivery advantage. Market is clearly pricing in significant execution risk. Key watch: upcoming clinical data + cash runway (possible dilution risk). Not for the faint of heart, but risk/reward starts to look asymmetric at these levels.
0 · Reply
EldarGman
EldarGman Apr. 16 at 5:54 PM
$BTM Nice stock🚀🚀🚀 $SIDU $GOSS $ROLR
0 · Reply
redbeamgold
redbeamgold Apr. 16 at 1:09 PM
$GOSS are we expecting a pr on the scans this month?
1 · Reply
Waagie
Waagie Apr. 16 at 11:07 AM
$GOSS 💪
0 · Reply
Hahaha111
Hahaha111 Apr. 15 at 2:45 PM
$GOSS is 0.50 likely the top - short term? or will this continue to a dollar
1 · Reply
Cheaslea76
Cheaslea76 Apr. 15 at 2:43 PM
$GOSS 😁💪🏽🫶🏽😎
0 · Reply
Sinimini
Sinimini Apr. 15 at 1:40 PM
$GOSS
0 · Reply
Waagie
Waagie Apr. 15 at 1:39 PM
$GOSS
0 · Reply
Fettenajs2026
Fettenajs2026 Apr. 15 at 1:35 PM
$GOSS 0.50 here we come
0 · Reply
Waagie
Waagie Apr. 15 at 1:35 PM
$GOSS 🚀🌙
0 · Reply
Waagie
Waagie Apr. 14 at 2:29 PM
$GOSS let’s go 🚀
0 · Reply
Bli1
Bli1 Apr. 14 at 7:02 AM
$GOSS there is a pivotal catalyst around the corner, the scans of the pulmonary blood vessel branches. If there is further proof of regeneration as previously observed, we might be back above a buck, otherwise we remain in the dire straights. So, we have potential and we have risk.
2 · Reply
Waagie
Waagie Apr. 14 at 4:54 AM
$GOSS max pain is .50 cents
0 · Reply
Havokmdk
Havokmdk Apr. 13 at 5:42 PM
$GOSS any news on when they meet with the FDA
1 · Reply
Bli1
Bli1 Apr. 11 at 9:13 AM
$GOSS next couple of weeks should be fun. North of 50ct should be achievable.
0 · Reply
Peterson28
Peterson28 Apr. 10 at 10:41 PM
$GOSS Who dumb dumb sold yesterday post market?
0 · Reply
trailbosstraders
trailbosstraders Apr. 10 at 2:56 PM
$GOSS pump to let people out before reverse split
0 · Reply
Twills08
Twills08 Apr. 10 at 2:06 PM
$GOSS Whether you like them or hate them, GOSS is moving…
0 · Reply
Sinimini
Sinimini Apr. 10 at 1:47 PM
$GOSS 1 USD soon ❤️
0 · Reply
Bullishontherize
Bullishontherize Apr. 10 at 1:43 PM
$GOSS
0 · Reply
chevy2345
chevy2345 Apr. 10 at 1:43 PM
$GOSS so what’s the deal with GOSS? Is all hope lost. Is there a chance that phase 3 results will be amended? Any opp here? I’m down big but thinking long term.
0 · Reply